Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNARE: Capivasertib and iADT in High-Risk Localized Prostate Cancer
NCT05593497Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- May 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in prostate cancer (PCa), sponsored by VA Office of Research & Development. Started May 2024; status: recruiting.
02
Drugs
capivasertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05593497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593497.